Germline testing for breast cancer patients in England: illogical to prioritise grade 1 breast cancer aged 30-39 over grade 3 aged 40-49 years?

J Med Genet. 2024 Jul 25:jmg-2024-110183. doi: 10.1136/jmg-2024-110183. Online ahead of print.

D Gareth Evans^{1

2}, Sacha J Howell^{2

3}, George J Burghel⁴, Claire Forde⁵, Fiona Lalloo⁶, Miriam J Smith⁷, Anthony Howell⁸, Ashu Gandhi⁹, Emma Roisin Woodward¹⁰

¹ Genomic Medicine, University of Manchester - The Victoria University of Manchester Campus, Manchester, UK gareth.d.evans@manchester.ac.uk.
² Manchester Academic Health Science Centre, Manchester, UK.
³ The Christie NHS Foundation Trust, Manchester, UK.
⁴ Genomic Diagnostic Laboratory, Manchester University NHS Foundation Trust, Manchester, UK.
⁵ Clinical Genetics Service, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
⁶ Clinical Genetics Service, Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
⁷ Genetic Medicine, University of Manchester, Manchester, UK.
⁸ Prevent Breast Cancer Centre, Manchester, UK.
⁹ Prevent Breast Cancer Centre, Prevent Breast Cancer Centre, Wythenshawe Hospital Manchester Universities Foundation Trust, Wythenshawe, Manchester, UK.
¹⁰ Manchester Centre for Genomic Medicine, Central Manchester NHS Foundation Trust, Manchester, UK.

No abstract available

Keywords: Gene Frequency; Genetic Diseases, Inborn.